Introduction
============

Pancreas cysts (PCs) are being diagnosed with increasing frequency given the widespread use of cross-sectional imaging in our health care system [@JR1753-1] . PCs can be broadly categorized as either non-neoplastic or neoplastic, with the latter being estimated as high as 13.5 % in the general population [@JR1753-2] . Accurate diagnosis and risk stratification of neoplastic cysts are crucial as to provide guidance for the most appropriate management strategy.

The optimal diagnostic approach to PCs remains unclear as there is currently no single test that can reliably differentiate non-neoplastic PCs from those lesions with malignant potential or harboring malignancy. Given the well-recognized limitations of imaging alone [@JR1753-2] [@JR1753-3] [@JR1753-4] , EUS-guided fine-needle aspiration (EUS-FNA) for cytology and cyst fluid analysis is the commonly performed guideline endorsed test for aid with diagnosis and risk stratification [@JR1753-4] [@JR1753-5] [@JR1753-6] [@JR1753-7] [@JR1753-8] [@JR1753-9] [@JR1753-10] . FNA cytology is often limited by the scant cellularity within the cyst fluid [@JR1753-11] [@JR1753-12] . While cyst fluid carcinoembryonic antigen (CEA) has been traditionally used to differentiate mucinous versus non-mucinous PCs [@JR1753-13] , it has modest diagnostic accuracy and does not discriminate between benign and malignant mucinous cysts [@JR1753-14] [@JR1753-15] .

Recently, a through-the-needle microforceps device (Moray Microforceps, US Endoscopy, Mentor, Ohio, United States) was introduced for EUS-guided tissue sampling of PCs. The microforceps can be advanced through the lumen of a standard 19-gauge EUS-FNA needle for through-the-needle tissue biopsy (TTNB) of PCs. Since its introduction, there have been several studies reporting on the performance of the TTNB [@JR1753-16] [@JR1753-17] [@JR1753-18] [@JR1753-19] [@JR1753-20] [@JR1753-21] [@JR1753-22] [@JR1753-23] [@JR1753-24] [@JR1753-25] [@JR1753-26] [@JR1753-27] [@JR1753-28] . We performed a systematic review and meta-analysis of the current literature to better assess the feasibility, safety, and diagnostic yield of TTNB as compared to EUS-FNA in the evaluation of PCs.

Methods
=======

Search strategy
---------------

We conducted a comprehensive search of four electronic databases (MEDLINE through Pubmed, EMBASE, Cochrane, and Web of Science) for all relevant studies with the last search performed in July 2019. The search was performed with the assistance of an experienced medical librarian.

The PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines were followed. Key terms used in the search query included a combination of the following: "Endoscopic ultrasound-guided through the needle microforceps", "microforceps", "micro-forcep", "pancreas AND microforceps", "through the needle", ("pancreas AND through the needle,") ("pancreas" AND "through the needle" AND "EUS"), ("pancreatic cysts" AND "through the needle"), ("pancreatic cyst" AND "moray"), "moray micro-forceps," ("microforceps" AND "pancreas"). We attempted to identify additional studies by reviewing the reference list of all included studies and by manual search in order to retrieve other articles that may have been missed on the initial search strategy. Using the predefined inclusion and exclusion criteria, two investigators (S.P., D.W.) independently screened the title and abstract of all studies identified in the primary search. The full text of all relevant studies was subsequently reviewed. Discrepancies were resolved by consensus and by discussion with the co-authors (P.V.D., D.Y.).

Study selection
===============

All studies were screened based on the predefined inclusion and exclusion criteria. Studies were included if they: (1) were retrospective or prospective, case-control or cohort studies and clinical trials (including randomized controlled trials); (2) reported EUS-TTNB of pancreas cysts; and (3) included data on cytology and/or histology for EUS-TTNB. Studies were excluded if: (1) they included fewer than five cases; (2) animal studies; (3) EUS-TTNB was performed in non-cystic pancreatic lesions, (3) cytologic or histological diagnosis for EUS-TTNB was not provided; or (4) were publications in a language other than English.

In the case of publications from the same group of authors, we contacted the authors as to determine whether these were from the same cohort. If publications were from the same cohort or if this could not be verified, then only data from the most recent and/or most comprehensive study was included. In our search query, we encountered one such study by Kovacevic et al [@JR1753-20] .

Data extraction and quality assessment
--------------------------------------

Three investigators (S.P., D.W., D.Y.) independently extracted data from each study by using a standardized data collection form, which included: (1) study author; (2) year of publication; (3) study period; (4) patient demographics; (5) pancreatic cyst characteristics (i. e. size, morphology, location); (6) cyst fluid analysis; (7) cytology from EUS-FNA; (8) histology from EUS-TTNB (9) adverse events (AES); and (10) surgical pathology.

Contingency 2 × 2 tables were constructed with information of true positive, false positive, true negative, and false negative for TTNB discrimination between mucinous and non-mucinous cysts, with surgical pathology as the reference standard.

The quality of the studies was assessed by using a modified Newcastle Ottawa Scale (NOS) for cohort studies [@JR1753-29] . The modified NOS consisted of 6 components: representative of the average population (1 point for population-based studies, 0.5 point for multi-center studies, 0 point for single-center hospital-based study), large cohort size (1 point \> 50 patients, 0.5 point for 30--49 patients, and 0 point \< 30 patients); information on how a mucinous cyst was diagnosed (1 point if reported with clarity; 0 point if not reported); information on the specific cyst diagnosis obtained by FNA and TTNB (1 point if reported for both; 0.5 if reported for either FNA or TTNB, 0 point if not reported); information on AEs (1 point if reported, 0 point if not reported); information on concordance between FNA, TTNB and surgical pathology (1 point if reported, 0.5 if reported for either FNA or TTNB, 0 point if not reported). Studies with scores ≥ 5, 3--4, and ≤ 2 were suggestive of high, moderate, and low quality, respectively.

Study aim and definitions
-------------------------

The primary aim of this study was to perform a systematic review and meta-analysis to assess the feasibility, safety, and diagnostic yield of EUS-TTNB versus FNA in PCs. A secondary aim was to determine the pooled sensitivity and specificity of TTNB for mucinous cysts. Technical feasibility was defined as successful passage of the microforceps through the indwelling EUS needle and completion of intended tissue acquisition (EUS-TTNB). Diagnostic yield was defined as the number of cases in which a diagnosis was attained divided by the total of number of cases. The concordance rate was defined as the number of cases in which TTNB or FNA matched the final surgical diagnosis divided by the total number of surgical specimens for that category. TTNB diagnostic accuracy parameters for mucinous cysts were calculated from eligible studies by using the surgical pathology as the reference standard. AEs were defined as any deviation from the expected post-procedural clinical course. Intracystic hemorrhage was defined as the presence of blood within a cyst as identified on EUS or subsequent cross-sectional imaging.

Statistical analysis
--------------------

The data was analyzed with Review Manager 5.2 (RevMan, The Nordic Cochrane Center, The Cochrane Collaboration, 2012) for computation of comparative forest plots and funnel plots. Pooled proportions were calculated from the weighted means of individual proportions and funnel plots were calculated using STATA (Stata Statistical Software, STATA 15, College Station, Texas, United States). Subgroup analysis were also performed to compare EUS-TTNB verses EUS-FNA and reported as odds ratios (OR) with 95 % confidence intervals (CI) calculated using the Mantel-Haenszel method. The heterogeneity estimate of the studies was calculated using the Cochran Q test I ^2^ statistic. Values of \< 30 %, 30 % to 60 %, 61 % to 75 %, and \> 75 % were considered low, moderate, substantial, and considerable heterogeneity, respectively [@JR1753-30] . A fixed- or random-effects model was applied based on heterogeneity. In the eligible studies, the pooled sensitivity and specificity was calculated. A receiver operating characteristics (ROC) curve could not be calculated as none of the studies included reported false positive results for TTNB in the diagnosis of mucinous cysts. Funnel plots were visually inspected for publication bias; Egger's test was not performed to test for funnel plot asymmetry as this is not appropriate for meta-analysis with less than 10 studies [@JR1753-31] [@JR1753-32] [@BR1753-33] .

Results
=======

Search results
--------------

Our primary search strategy yielded 1752 studies, of which 176 were duplicates. Of the remaining 1576 publications, 1525 were excluded after screening titles and abstracts. Full text review was subsequently performed on 51 studies using our predefined inclusion and exclusion criteria. Eight studies with a total of 426 cases were included in the final meta-analysis [@JR1753-21] [@JR1753-22] [@JR1753-23] [@JR1753-24] [@JR1753-25] [@JR1753-26] [@JR1753-27] [@JR1753-28] . The study flow diagram is shown in [Fig. 1](#FI1753-1){ref-type="fig"} .

![ PRISMA Flowchart of included studies. From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097](10-1055-a-1119-6543-i1753ei1){#FI1753-1}

Study characteristics and quality assessment
--------------------------------------------

Study characteristics are summarized in [Table 1](#TB1753-1){ref-type="table"} . All articles were cohort studies (7 retrospective and 1 prospective), study period between 2014 to 2018, and originating from the United States (n = 5) or Europe (n = 3). The mean age ranged between 50 to 70 years with 59.9 % (255 out of 426) being female. Most studies reported a mean pancreas cyst size between 28.2 mm to 40.7 mm. Pancreas cyst location was reported in all studies except by Kovacevic et al [@JR1753-19] . Most cysts were primarily located in the body/tail (64.6 %) followed by head/uncinated process (35.4 %). The median number of passes for EUS-TTNB was three, with two studies reporting tissue acquisition until a visible specimen was obtained [@JR1753-22] [@JR1753-26] .

###### Study characteristics.

  Study                         Study design       Patients (n)   Age (years)   Gender   Pancreas cyst (mm)   Cyst location               Unilocular/septated   CEA ≥ 192 ng/mL n, (%)   \# Passes for TTNB   Patients who underwent surgery n (%)                                   
  ----------------------------- ------------------ -------------- ------------- -------- -------------------- --------------------------- --------------------- ------------------------ -------------------- -------------------------------------- ------------------------------- -------------
  Barresi 2018 [@JR1753-21]     MC Retrospective    56            58            17       39                   Mean 38.6 (range 16--55)    24                    32                       32/24                18 (32.1 %)                            Mean 3.1 (range 1--5)           15 (26.8 %)
  Basar 2018 [@JR1753-22]       MC Retrospective    42            69            19       23                   Mean 28.2 (range 12--60)    16                    26                       17/25                12 (28.6 %)                            Until visible tissue obtained    7 (16.7 %)
  Kovacevic 2018 [@JR1753-23]   SC Retrospective    31            70            16       15                   Median 30 (range 12--130)   NR                    NR                       NR                   6 (19.4 %)                             Median 3 (IQR 2--4)              4 (12.9 %)
  Mittal 2018 [@JR1753-24]      SC Retrospective    27            65            11       16                   Mean 37.8 (15--70)          14                    13                       NR                   12 (44.4 %)                            Mean 3.7 (range 1--7)            5 (18.5 %)
  Yang 2018 [@JR1753-25]        MC Retrospective    47            66            21       26                   Mean 30.8 (11.6--110)       16                    31                       16/35                9 (19.1 %)                             Median 3 (IQR 2--4)              8 (17.0 %)
  Zhang 2018 [@JR1753-26]       SC Retrospective    48            70            23       25                   Mean 31 (range 12--60)      13                    35                       NR                   13 (27.1 %)                            Until visible tissue obtained   10 (20.8 %)
  Yang 2019 [@JR1753-27]        MC Prospective     114            64            50       64                   Mean 35.1 (IQR 20--41)      39                    75                       68/36                32 (28.1 %)                            Median 3 (IQR 2--4)             23 (20.2 %)
  Crino 2019 [@JR1753-28]       SC Retrospective    61            50            14       47                   Mean 40.7 (range 16--75)    18                    43                       34/27                N/A                                    Median 3 (range 2--5)           20 (32.8 %)

CEA, carcinoembryonic antigen; MC, multicenter; SC, single center; IQR, interquartile range

The quality of the studies was assessed by using the modified NOS scale as shown in [Table 2](#TB1753-2){ref-type="table"} . None of the studies were population based; with equal number of single center (n = 4) and multicenter (n = 4) studies. Three studies had \> 50 patients [@JR1753-21] [@JR1753-27] [@JR1753-28] , four studies included 30--49 patients [@JR1753-22] [@JR1753-23] [@JR1753-25] [@JR1753-26] , and one study \< 30 patients [@JR1753-24] . Six out of the eight studies provided clear definitions on how a mucinous cyst was diagnosed [@JR1753-21] [@JR1753-22] [@JR1753-25] [@JR1753-26] [@JR1753-27] [@JR1753-28] . Six of the 8 studies provided information on the specific cyst type diagnosis obtained via TTNB and FNA [@JR1753-22] [@JR1753-23] [@JR1753-24] [@JR1753-25] [@JR1753-26] [@JR1753-27] . All studies provided information on adverse events. Six of the eight studies provided information on FNA cytology, TTNB histology and the corresponding surgical pathology. Overall, three studies were considered to be of high quality [@JR1753-22] [@JR1753-25] [@JR1753-28] , five of medium quality [@JR1753-21] [@JR1753-23] [@JR1753-24] [@JR1753-26] [@JR1753-28] , and none of low quality.

###### Study quality assessment using the modified Newcastle Ottawa Scale.

  Study                         Representative of average population   Cohort Size   Information on how a mucinous cyst was diagnosed   Information on specific diagnosis by FNA and TTNB   Information on adverse events   Data on TTNB, FNA and corresponding surgical pathology   Total
  ----------------------------- -------------------------------------- ------------- -------------------------------------------------- --------------------------------------------------- ------------------------------- -------------------------------------------------------- -------
  Barresi 2018 [@JR1753-21]     0.5                                    1             1                                                  0.5                                                 1                               0.5                                                      4.5
  Basar 2018 [@JR1753-22]       0.5                                    0.5           1                                                  1                                                   1                               1                                                        5
  Kovacevic 2018 [@JR1753-23]   0                                      0.5           0.5                                                1                                                   1                               1                                                        4
  Mittal 2018 [@JR1753-24]      0                                      0             0.5                                                1                                                   1                               1                                                        3.5
  Yang 2018 [@JR1753-25]        0.5                                    0.5           1                                                  1                                                   1                               1                                                        5
  Zhang 2018 [@JR1753-26]       0                                      0.5           1                                                  1                                                   1                               0                                                        3.5
  Yang 2019 [@JR1753-27]        0.5                                    1             1                                                  1                                                   1                               1                                                        5.5
  Crino 2019 [@JR1753-28]       0                                      1             1                                                  0.5                                                 1                               1                                                        4.5

FNA, fine-needle aspiration; TTNB, through-the-needle biopsy

Feasibility of EUS-TTNB in the evaluation of pancreatic cysts
-------------------------------------------------------------

In all, EUS-TTNB was successfully performed in 418 of 426 cases, for a pooled technical success of 98.2 % (95 % CI: \[96.8--99.3 %\]; I ^2^  = 45.5) ( [Fig. 2](#FI1753-2){ref-type="fig"} ). EUS-TTNB failed in five cases because the microforceps could not be advanced through the angulated EUS-FNA needle via a transduodenal approach [@JR1753-23] [@JR1753-25] . In the remainder three cases, EUS-TTNB was not performed due to the presence of interposing vessels between the EUS needle and cyst (n = 1), as a result of insufficient sedation and transient hypoxia prior to EUS-TTNB (n = 1), or in the setting of a bloody aspirate with EUS-FNA (n = 1) [@JR1753-25] [@JR1753-28] .

![ Pooled technical success of EUS-TTNB in the evaluation of pancreatic cysts (Fixed-effect Model).](10-1055-a-1119-6543-i1753ei2){#FI1753-2}

Diagnostic yield of TTNB versus FNA in pancreas cysts
-----------------------------------------------------

### Specific cyst type

The specific cyst type diagnosis obtained via TTNB histology and FNA cytology from all the studies in this meta-analysis are summarized in [Table 3](#TB1753-3){ref-type="table"} . The pooled diagnostic yield for a specific cyst type was significantly higher with TTNB histology (72.5 %; 95 % CI: \[60.6--83.0\]) than FNA cytology (38.1 %; 95 % CI: \[18.0--60.5\]). Furthermore, in comparator analysis the diagnostic yield was significantly higher with TTNB compared to FNA (OR: 9.37; 95 % CI: \[5.69--15.42\]), with moderate heterogeneity among the studies (I ^2^  = 48) ( [Fig. 3](#FI1753-3){ref-type="fig"} ).

###### Specific cyst type diagnoses obtained via TTNB histology and FNA cytology [1](#FN1753-1){ref-type="table-fn"} .

                                                                Study                                                                                                             
  ------------------------------------------------------------- ------- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---------------------------------------- ---- ---- ---- ---- ----
  Mucinous cyst                                                 NS      19   0    8    6    19    8    9   10   26   26                                       28   11   61   NS   23
  Fibrous non-epithelium/inflammatory cells (pseudocyst)        NS       7   --   --   1     2   13   10    2    2                                                 10   14   NS    2
  Serous cystadenoma                                            NS      14   0    3    0     4    0    4    0    4    2 [1](#FN1753-1){ref-type="table-fn"}    3    1    5   NS   13
  Mucinous cyst with malignant transformation; adenocarcinoma   NS       3   1    2    1     0    1   0     1    0    1                                        1    0    2   NS    0
  Neuroendocrine tumor                                          NS      --   1    1    --   --    0    1   --   --   --                                       --    1    6   NS    5
  Acinar cystadenoma                                            NS      --   1    1    --   --   --   --   --   --    0                                        1   --   --   NS    0
  Benign glandular epithelium                                   NS      --   --   --   --   --   --   --    9    7   --                                       --   18    6   NS    0
  Solid pseudopapillary tumor                                   NS      --   --   --   --   --   --   --   --   --   --                                       --    0    1   NS    1
  Squamoid cyst                                                 NS      --   --   --   --   --   --   --   --   --   --                                       --   --   --   NS    3
  Lymphangioma                                                  NS      --   --   --   --   --   --   --   --   --   --                                       --   --   --   NS    2
  Lymphoepithelial cyst                                         NS      --   --   --   --   --   --   --   --   --   --                                       --   --   --   NS    1
  Undefined                                                     NS      --   --   --   --   --   --   --   --   --   --                                       --   --   --   NS   11

FNA, fine-needle aspiration; TTNB, through-the-needle biopsy; NS, not specified

Diagnosis was based on cyst fluid analysis and cytology

![ Pooled diagnostic yield of TTNB histology vs FNA cytology for a specific cyst type diagnosis (Random-Effect Model).](10-1055-a-1119-6543-i1753ei3){#FI1753-3}

### Mucinous cysts

The pooled diagnostic yield for a mucinous cyst was 56.2 % (95 % CI: \[45.1--67.0\]) with TTNB and 29.5 % (95 % CI: \[15.5--45.9\]) with FNA, respectively. Cyst fluid CEA levels were specified in 7 out of the 8 studies [@JR1753-21] [@JR1753-22] [@JR1753-23] [@JR1753-24] [@JR1753-25] [@JR1753-26] [@JR1753-27] . The pooled rate of PCs with CEA ≥ 192 ng/mL was 28.2 % (95 % CI: \[23.7--32.8\]). Overall, in comparator analysis the diagnostic yield for a mucinous cyst was significantly higher with TTNB histology when compared to either FNA cytology (OR: 3.86; 95 % CI: \[2.0--7.44\], I ^2^  = 72 %) ( [Fig. 4a](#FI1753-4){ref-type="fig"} ) or CEA ≥ 192 ng/mL (OR: 2.94; 95 % CI: \[1.66--5.21\], I ^2^  = 67 %) ( [Fig. 4b](#FI1753-4){ref-type="fig"} ).

![Pooled diagnostic yield of TTNB histology vs FNA cytology for mucinous cysts (Random-Effect Model). **b** Pooled diagnostic yield of TTNB histology vs. cyst fluid CEA ≥ 192 ng/mL for mucinous cysts (Random-Effect Model). **c** Pooled diagnostic yield of TTNB histology vs FNA cytology for serous cystadenoma (Fixed-Effect Model).](10-1055-a-1119-6543-i1753ei4){#FI1753-4}

### Serous cystadenoma

Six studies provided information on serous cystadenoma based on both TTNB histology and FNA cytology [@JR1753-22] [@JR1753-23] [@JR1753-24] [@JR1753-25] [@JR1753-26] [@JR1753-27] . Among these studies, the pooled diagnostic yield for a serous cystadenoma was significantly higher with TTNB (12.4 %; 95 % CI: \[7.3--18.6\]) as compared to FNA (1.2 %; 95 % CI: \[0.3--2.5\]). In comparator analysis, the diagnostic yield of a serous cystadenoma was greater with TTNB compared to FNA (OR: 5.35; 95 % CI: \[2.02--14.16\]), with low heterogeneity among the studies (I ^2^  = 0) ( [Fig. 4c](#FI1753-4){ref-type="fig"} ).

TTNB and FNA concordance with surgical pathology
------------------------------------------------

Ninety two patients in the 8 studies included in this meta-analysis underwent surgery for their PCs. Six studies provided information on the respective TTNB histology and FNA cytology for each surgical pathology specimen [@JR1753-22] [@JR1753-23] [@JR1753-24] [@JR1753-25] [@JR1753-27] [@JR1753-28] .

### Diagnosis of specific cyst type

The pooled concordance of TTNB and FNA with surgical pathology for a specific cyst type were 82.3 % (95 % CI: \[71.9--90.7\]) and 26.8 % (95 % CI: \[17.0--37.8\]), respectively. Compared to FNA cytology, TTNB histology was significantly more likely (OR: 13.49; 95 % CI: \[3.49--52.29\]) to match the diagnosis on surgical pathology; with moderate heterogeneity between the studies (I ^2^  = 48 %) ( [Fig. 5](#FI1753-5){ref-type="fig"} ).

![ Pooled concordance of TTNB histology vs FNA cytology with surgical pathology for a specific cyst type (Random-Effect Model).](10-1055-a-1119-6543-i1753ei5){#FI1753-5}

### Diagnosis of mucinous cysts

The pooled concordance for mucinous cysts was also higher for TTNB (89 %; 95 % CI: \[80.0--95.0\]) vs FNA (41 %; 95 % CI: \[28--55\]). Compared to FNA, TTNB was significantly more likely (OR: 8.93; 95 % CI: \[1.96--40.77\]) to match the diagnosis of mucinous cyst with surgical pathology; with low heterogeneity detected (I ^2^  = 29 %) ( [Fig. 6a](#FI1753-6){ref-type="fig"} ). Using the surgical pathology as the reference standard, the overall sensitivity and specificity of TTNB for mucinous cysts were 90.1 % (95 % CI: \[78.4--97.6\]; I ^2^  = 36.5 %) and 94 % (95 % CI: \[81.5--99.7\]; I ^2^  = 0), respectively ( [Fig. 6b](#FI1753-6){ref-type="fig"} , [Fig. 6c](#FI1753-6){ref-type="fig"} ).

![Pooled concordance of TTNB histology vs FNA cytology with surgical pathology for a mucinous cyst (Random-Effect Model). **b** Pooled sensitivity of TTNB histology for diagnosing a mucinous cyst using surgical pathology as reference standard (Random-Effect Model). **c** Pooled specificity of TTNB histology for diagnosing a mucinous cyst using surgical pathology as reference standard (Fixed-Effect Model).](10-1055-a-1119-6543-i1753ei6){#FI1753-6}

### Diagnosis of histological grading of mucinous cysts

Four studies provided information on histological grading of mucinous cysts on TTNB histology, FNA cytology, and corresponding surgical pathology [@JR1753-22] [@JR1753-25] [@JR1753-27] [@JR1753-28] . The pooled concordance with the histological grade of a mucinous cyst on surgical pathology was significantly higher with TTNB (75.6 %; 95 % CI: \[62.3--86.8\]) versus FNA (26 %; 95 % CI: \[6.7--52.3\]). Furthermore, TTNB in comparison to FNA was significantly more likely to match the histologic grade compared to surgical pathology (OR: 10.4; 95 % CI: \[2.93--36.93\]); with low heterogeneity (I ^2^  = 0) ( [Fig. 7](#FI1753-7){ref-type="fig"} ).

![ Pooled concordance of TTNB histology vs FNA cytology with histological grading of mucinous cysts on surgical pathology (Fixed-Effect Model)](10-1055-a-1119-6543-i1753ei7){#FI1753-7}

Adverse events
--------------

The pooled rate of AEs was 7.0 % (95 % CI: \[2.3--14.1\]; I ^2^  = 82.9) ( [Fig. 8a](#FI1753-8){ref-type="fig"} ). The pooled occurrence for intracystic hemorrhage and acute pancreatitis were 5.0 % (95 % CI: \[1.2--11.2\]; I ^2^  = 82.6) and 2.3 % (95 % CI: \[0.5--5.3\]; I ^2^  = 62.5), respectively ( [Fig. 8b](#FI1753-8){ref-type="fig"} , [Fig. 8c](#FI1753-8){ref-type="fig"} ). None of the cases of intracystic hemorrhage required additional interventions. Among the 10 cases of acute pancreatitis reported, six did not require hospitalization [@JR1753-21] [@JR1753-25] [@JR1753-27] [@JR1753-28] , three were discharged within 24 to 48 hours with supportive care [@JR1753-25] [@JR1753-28] , whereas one developed a pseudocyst that required endoscopic drainage [@JR1753-27] .

![Pooled adverse events with TTNB of pancreatic cysts. **b** Pooled occurrence of intracystic hemorrhage with TTNB of pancreatic cysts. **c** Pooled occurrence of acute pancreatitis with TTNB of pancreatic cysts.](10-1055-a-1119-6543-i1753ei8){#FI1753-8}

Publication bias
----------------

Funnel plots have been included in the supplementary material ( **Supplementary Fig. 9** ). There was no evidence of substantial publication bias on visual inspection of the funnel plots for any of the analyses except for the calculation of the pooled concordance rate between TTNB, FNA and surgical pathology for a specific cyst type diagnosis, which is in part due to precision bias being skewed by the two larger studies favoring TTNB histology concordance with surgical pathology [@JR1753-27] [@JR1753-28] .

Discussion
==========

Accurate diagnosis and risk stratification of PCs is of utmost importance as it may allow the early detection and management of PCs with malignant potential, while limiting unnecessary interventions in most inconsequential benign PCs. In this systematic review and meta-analysis, we evaluated the performance of TTNB of PCs using a novel microforceps device.

The overall estimated pooled technical success of TTNB with the microforceps was very high (98.2 %), supporting its applicability in the diagnosis of a broad range of PCs, irrespective of cyst size or location. The microforceps device permits targeted tissue acquisition from the cyst wall, septations and/or mural nodules for histological evaluation, which in turn, potentially increases the likelihood of obtaining a specific cyst diagnosis as compared to FNA cytology. In this meta-analysis, the overall diagnostic yield for a specific cyst type was significantly higher with TTNB versus FNA (OR: 9.37; CI: \[5.7--15.4\]). The superior diagnostic yield of TTNB for a specific cyst type was further supported in this meta-analysis by the overall higher concordance of TTNB over FNA (OR: 13.49; CI: \[4.5--52.3\]) for a specific cyst diagnosis on surgical pathology. Differentiating between specific cyst types has significant clinical implications. For instance, SCAs are benign lesions that do not necessitate surveillance or intervention in the absence of symptoms. However, previous studies have demonstrated that FNA cytology has a low sensitivity for the diagnosis of SCA [@JR1753-34] [@JR1753-35] . Our results demonstrated that the diagnostic yield for serous cystadenoma was also significantly higher with TTNB as compared to FNA (OR: 5.35; CI: \[2.0--14.2\]). In aggregate, these findings suggest that TTNB can be helpful when elucidating a specific cyst type may impact subsequent care.

The limitations of EUS-FNA for the evaluation of mucinous cysts are well-recognized [@JR1753-4] [@JR1753-11] [@JR1753-12] and additional modalities are much needed to improve our diagnostic ability. In this study, the diagnostic yield for mucinous cysts was significantly higher with TTNB histology when compared to either FNA cytology (OR: 3.86; CI: \[2.0--7.4\]) or cyst fluid CEA ≥ 192 ng/mL (OR: 2.94; CI:\[1.7--5.2\]). Using surgical pathology as the reference standard, the pooled sensitivity and specificity of TTNB for mucinous cysts were 90.1 % and 94 %, respectively; with low heterogeneity among the studies. Indeed, our data demonstrated that TTNB was nearly 9-fold more likely to diagnose a mucinous cyst when compared to FNA cytology (OR: 8.93; CI: \[2.0--40.8\]); and hence, should be entertained as part of the multi-modality approach in the evaluation of PCs.

Accurate risk stratification of mucinous cysts is perhaps the most important yet also the most challenging step in the management of PCs. Cyst fluid analysis is not helpful as neither CEA nor molecular mutations correlate with histological grade. While relatively specific, the diagnostic accuracy of FNA cytology is often hindered by the suboptimal cellular specimen obtained from PCs [@JR1753-11] [@JR1753-36] . In this meta-analysis, we demonstrate that the concordance rate with the histological grade among surgically resected mucinous cysts was 10-fold higher with TTNB histology when compared to FNA cytology (OR 10.41; CI: \[2.9--37.0\]) with low heterogeneity. Given the high rate of tissue adequacy for histological grading, TTNB may prove to add significant value, particularly when triaging patients with no overt "high-risk" cyst features.

The estimated pooled occurrence of AEs associated with TTNB was 7 %, with the calculated rate of intracystic hemorrhage and acute pancreatitis being 5 % and 2.3 %, respectively. Given the lack of current data to evaluate for risk factors, we can only speculate that the more aggressive mode of tissue acquisition with TTNB may account for the higher rates of adverse events. The study by Crino et al [@JR1753-28] suggests that two TTNB macroscopically visible specimens allowed reaching a 100 % histological adequacy and therefore additional attempts at TTNB may not improve the yield but rather increase the risk of AEs. Further studies are needed to help define not only the optimal number of passes but also the preferred tissue acquisition technique with this device.

This study has several strengths. We performed a systematic literature search that was comprehensive with well-defined inclusion and exclusion criteria, and the quality of the studies was rigorously assessed based on the pre-defined parameters in the modified NOS. All subjects in the included studies underwent both EUS-FNA and TTNB for the comparative outcome measures, thereby serving as their own control and reducing variance. Furthermore, it is important to highlight that we strictly used surgical pathology as the reference criterion when calculating the diagnostic accuracy of TTNB for mucinous cysts. We also acknowledge the limitations. Most included studies were small in sample size and retrospective in design, thereby contributing to selection and reporting bias. Furthermore, publication bias was observed for some of the subgroup calculations in this meta-analysis, primarily driven by the small cohort size of each study and the limited number of studies available. In addition, all studies were performed at tertiary care referral centers and thus not representative of the general population. TTNB is not regarded as a standard method in the evaluation of pancreatic cysts, and additional data are needed to further determine its role in the diagnostic algorithm of these lesions. In addition, while our data suggested higher odds of obtaining a correct diagnosis with TTNB as compared to FNA, these results should be interpreted with caution given the large confidence intervals. There was considerable heterogeneity among the studies in the overall analysis comparing diagnostic yield of TTNB vs FNA for specific cyst type, mucinous cyst, and the estimated adverse event rate with TTNB. Possible explanations include variability in: (1) indications for EUS-FNA and TTNB; (2) cyst sampling technique and number of passes for FNA cytology and TTNB histology; (3) pancreas cyst size and morphology; (4) inclusion of cyst fluid analysis and cytology for the evaluation of FNA performance [@JR1753-26] ; and (5) patient follow-up post-procedure. We were not able to further evaluate the data based on these parameters given that most studies were inconsistent in the reporting of this information and when available, the outcomes were not categorized according to these findings. Even though a meta-regression analysis could not be performed for these reasons, no evidence of significant heterogeneity was found with regards to the diagnostic accuracy of TTNB for mucinous cysts or in its superiority over FNA in its correlation with a diagnosis of mucinous cyst and histological grade using surgery as reference standard.

Conclusion
==========

In conclusion, our meta-analysis demonstrates that TTNB has a high sensitivity and specificity for distinguishing mucinous from non-mucinous cysts and may be superior to FNA cytology in risk stratifying mucinous cysts and providing a specific cyst diagnosis. Future well-designed comparative studies between TTNB and FNA in the evaluation of PCs are needed to corroborate these results.
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